Skip to main content

Table 1 Baseline demographics for the mITT population

From: A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis

Characteristic

ETN 50 mg–ETN 25 mg (n = 21)

ETN 25 mg–ACT 10 mg (n = 19)

ACT 10 mg (n = 18)

Total (N = 58)

Mean age, y (SD)

38.6 (9.5)

35.5 (8.8)

42.4 (12.0)

38.8 (10.3)

Mean height, cm (SD)

169.5 (9.3)

171.7 (5.5)

170.9 (6.8)

170.6 (7.4)

Mean weight, kg (SD)

74.1 (16.0)

74.0 (11.6)

74.2 (9.8)

74.1 (12.7)

Gender, n (%)

    

 Male

16 (76.2 %)

17 (89.5 %)

15 (83.3 %)

48 (82.8 %)

Cigarette status, n (%)

    

 Prior cigarette usage

5 (23.8 %)

5 (26.3 %)

3 (16.7 %)

13 (22.4 %)

 Current cigarette usage

10 (47.6 %)

11 (57.9 %)

10 (55.6 %)

31 (53.5 %)

 No

6 (28.6 %)

3 (15.8 %)

5 (27.8 %)

14 (24.1 %)

Alcohol status, n (%)

    

 Ex-drinker

2 (9.5 %)

2 (10.5 %)

2 (11.1 %)

6 (10.3 %)

 Current-drinker

13 (61.9 %)

13 (68.4 %)

11 (61.1 %)

37 (63.8 %)

 No

6 (28.6 %)

4 (21.1 %)

5 (27.8 %)

15 (25.9 %)

Prior therapies for psoriasis, n (%)

    

 Methotrexate

2 (9.5 %)

1 (5.3 %)

0

3 (5.2 %)

 Cyclosporine

2 (9.5 %)

2 (10.5 %)

1 (5.6 %)

5 (8.6 %)

 PUVA

0

3 (15.8 %)

0

3 (5.2 %)

 Othera

12 (57.1 %)

12 (63.2 %)

10 (55.6 %)

34 (58.6 %)

  1. Abbreviations: ACT acitretin, CS clinically significant, ETN etanercept, mITT modified intent-to-treat population, NCS not clinically significant, PUVA psoralen plus ultraviolet A radiation therapy, SD standard deviation
  2. aIncludes systemic antimycobacterials, medication for treating alimentary tract and metabolism conditions, cardiovascular drugs, respiratory drugs, dermatologicals, and systemic hormonal preparations